Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwMyeloma 2018 | Myeloma 2018 day 1 highlights: precision medicine, epigenetics & novel targets

Keith Stewart, Kenneth Anderson and Sagar Lonial • 7 Sep 2018
iwMyeloma 2018
Multiple Myeloma

Keith Stewart, MB, ChB from the Mayo Clinic, Rochester, MN, is joined by Kenneth Anderson, MD, of the Dana-Farber Cancer Institute, Boston, MA, and Sagar Lonial, MD, of the Winship Cancer Institute of Emory University, Atlanta, GA, to share their highlights from day 1 of the Myeloma 2018 meeting, held in San Diego, CA. Hear their thoughts on precision medicine, immunotherapy, genomics, epigenetics, novel agents and more.

More from Keith Stewart

The future of myeloma therapy
Brian Walker et al. • 15 Apr 2023
Day 2 wrap-up: pushing myeloma boundaries 10:38
Day 2 wrap-up: pushing myeloma boundaries
Gareth Morgan et al. • 27 Mar 2022
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics 11:10
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
Faith Davies et al. • 26 Mar 2022
Immunotherapy in myeloma – where are we? 3:09
Immunotherapy in myeloma – where are we?
Keith Stewart • 30 Apr 2020

More from Kenneth Anderson

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more 13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Francesco Maura et al. • 24 Oct 2025
Defining high-risk multiple myeloma: recent advances in the field & future considerations
Francesco Maura et al. • 4 Nov 2024
Collaboration in the myeloma community 1:27
Collaboration in the myeloma community
Kenneth Anderson • 14 May 2022
The future of myeloma treatment and the possibility of cure 4:04
The future of myeloma treatment and the possibility of cure
Kenneth Anderson • 14 May 2022

More from Sagar Lonial

Practical advice for physicians treating patients with myeloma using belantamab mafodotin 0:37
Practical advice for physicians treating patients with myeloma using belantamab mafodotin
Sagar Lonial • 16 May 2025
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development 1:08
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development
Sagar Lonial • 16 May 2025
The ideal trial on the road to achieving the best outcome for patients with myeloma 0:41
The ideal trial on the road to achieving the best outcome for patients with myeloma
Sagar Lonial • 16 May 2025
The potential of CELMoDs for the treatment of multiple myeloma 0:50
The potential of CELMoDs for the treatment of multiple myeloma
Sagar Lonial • 16 May 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals